Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 12, 2012 - Issue 12
Submit an article Journal homepage
190
Views
6
CrossRef citations to date
0
Altmetric
Drug Profile

Ipilimumab in melanoma

Pol Specenier Antwerp University Hospital, Antwerp University, Wilrijkstraat 10, 2650 Edegem, Belgium. [email protected]
Pages 1511-1521 | Published online: 10 Jan 2014

References

  • Weir HK, Marrett LD, Cokkinides V et al. Melanoma in adolescents and young adults (ages 15–39 years): United States, 1999–2006. J. Am. Acad. Dermatol. 65(5 Suppl. 1), S38–S49 (2011).
  • Jemal A, Saraiya M, Patel P et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J. Am. Acad. Dermatol. 65(5 Suppl. 1), S17–S25.e1 (2011).
  • Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N. Engl. J. Med. 351(10), 998–1012 (2004).
  • Pollack LA, Li J, Berkowitz Z et al. Melanoma survival in the United States, 1992 to 2005. J. Am. Acad. Dermatol. 65(5 Suppl. 1), S78–S86 (2011).
  • Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev. Anticancer Ther. 9(5), 587–595 (2009).
  • Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18(2), 206–213 (2006).
  • Pennock GK, Waterfield W, Wolchok JD. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am. J. Clin. Oncol. doi:10.1097/COC.0b013e318209cda9 (2011) (Epub ahead of print).
  • Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175(11), 7746–7754 (2005).
  • Weber JS, O’Day S, Urba W et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26(36), 5950–5956 (2008).
  • Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
  • Wolchok JD, Hoos A, O’Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412–7420 (2009).
  • Tuma RS. New response criteria proposed for immunotherapies. J. Natl Cancer Inst. 100(18), 1280–1281 (2008).
  • O’Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm Phase II study. Ann. Oncol. 21(8), 1712–1717 (2010).
  • Maio M, Testori A, Ascierto PA, Ridolfi R, Santinami M, Pilla L. The NIBIT-M1 trial: activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases. J. Clin. Oncol. 30(Suppl.), Abstract 8259 (2012).
  • Patel SP, Hwu WJ, Kim KB, Papadopoulos NE, Hwu P, Radvanyi LG. Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma. J. Clin. Oncol. 30(Suppl.), Abstract 8514 (2012).
  • Prieto PA, Yang JC, Sherry RM et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 18, 2039–2047 (2012).
  • Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12(12), 1005–1016 (2005).
  • Hersh EM, O’Day SJ, Powderly J et al. A Phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest. New Drugs 29(3), 489–498 (2011).
  • Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase 2, dose-ranging study. Lancet Oncol. 11(2), 155–164 (2010).
  • Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebo-controlled, Phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15(17), 5591–5598 (2009).
  • Hamid O, Schmidt H, Nissan A et al. A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9, 204 (2011).
  • Revicki DA, van den Eertwegh AJ, Lorigan P et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual. Life Outcomes 10, 66 (2012).
  • Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517–2526 (2011).
  • Hodi FS, Oble DA, Drappatz J et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat. Clin. Pract. Oncol. 5(9), 557–561 (2008).
  • Margolin KA, Di Giacomo AM, Maio M. Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. Semin. Oncol. 37(5), 468–472 (2010).
  • Schartz NE, Farges C, Madelaine I et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res. 20(3), 247–250 (2010).
  • Weber JS, Amin A, Minor D, Siegel J, Berman D, O’Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a Phase 2 trial. Melanoma Res. 21(6), 530–534 (2011).
  • Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, Phase 2 trial. Lancet Oncol. 13(5), 459–465 (2012).
  • Khan KD, Callahan M, Postow MA, et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J. Clin. Oncol. 30(Suppl.), Abstract 8549 (2012).
  • Danielli R, Ridolfi R, Chiarion-Sileni V et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol. Immunother. 61(1), 41–48 (2012).
  • Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13(22 Pt 1), 6681–6688 (2007).
  • Harmankaya K, Erasim C, Koelblinger C et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med. Oncol. 28(4), 1140–1144 (2011).
  • Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can. J. Neurol. Sci. 36(4), 518–520 (2009).
  • Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J. Clin. Oncol. 30(6), e76–e78 (2012).
  • Lecouflet L, Verschoore M, Giard C et al. Orbital myositis associated with ipilimumab. Melanoma Res. 21(e-Suppl. A), Abstract e24 (2011).
  • Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N. Engl. J. Med. 365(18), 1747–1748 (2011).
  • Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N. Engl. J. Med. 361(2), 211–212 (2009).
  • Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology (Basel) 218(1), 69–70 (2009).
  • Vogel WV, Guislain A, Kvistborg P, Schumacher TN, Haanen JB, Blank CU. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J. Clin. Oncol. 30(2), e7–e10 (2012).
  • Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann. Oncol. 22(4), 991–993 (2011).
  • Bompaire F, Mateus C, Taillia H et al. Severe meningo-radiculo-nevritis associated with ipilimumab. Invest. New Drugs 30(6), 2407–2410 (2012).
  • Akhtari M, Waller EK, Jaye DL et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J. Immunother. 32(3), 322–324 (2009).
  • Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J. Immunother. 32(2), 203–205 (2009).
  • Du Four S, Wilgenhof S, Duerinck J et al. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur. J. Cancer 8(16), 3045–3051 (2012).
  • Thompson JA, Hamid O, Minor D et al. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a Phase II trial. J. Immunother. 35(1), 73–77 (2012).
  • Ackerman A, McDermott DF, Lawrence DP, Gunturi A, Flaherty KT, Giobbie-Hurder A. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. J. Clin. Oncol. 30(Suppl.), Abstract 8569 (2012).
  • Ku GY, Yuan J, Page DB et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116(7), 1767–1775 (2010).
  • Postow MA, Yuan J, Panageas KS, Bogatch K, Callahan M, Cheng M. Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3 mg/kg). J. Clin. Oncol. 30(Suppl.), Abstract 8575 (2012).
  • Di Giacomo AM, Danielli R, Calabrò L et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol. Immunother. 60(4), 467–477 (2011).
  • Wilgenhof S, Seghers AC, Dufour S et al. Single-center experience with ipilimumab in patients with pretreated advanced melanoma. J. Clin. Oncol. 30(Suppl.), Abstract e19026 (2012).
  • Kitano S, Postow MA, Cortez C et al. Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10 mg/kg to predict for overall survival in patients with metastatic melanoma. J. Clin. Oncol. 30(Suppl.), Abstract 2518 (2012).
  • Yuan J, Adamow M, Ginsberg BA et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl Acad. Sci. USA 108(40), 16723–16728 (2011).
  • Ellis SG, Wheater M, Tier K, Cazaly A, Smart J, Theaker J. Biomarker for benefit from ipilimumab: correlation of breadth of humoral tumor-antigen-specific immunity with outcome. J. Clin. Oncol. 30(Suppl.), Abstract 8566 (2012).
  • Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23(25), 6043–6053 (2005).
  • Lutzky J, Wolchok JD, Hamid O et al. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three Phase II clinical trials. J. Clin. Oncol. 27(Suppl. 15), Abstract 9034 (2009).
  • Ji RR, Chasalow SD, Wang L et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61(7), 1019–1031 (2012).
  • Shahabi V, Berman D, Chasalow SD et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-mediate gastrointestinal adverse events. J. Clin. Oncol. 30(Suppl.), Abstract 8593 (2012).
  • Shahabi V, Whitney G, Hamid O et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol. Immunother. 61(5), 733–737 (2012).
  • Wolchok JD, Weber JS, Hamid O et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 10, 9 (2010).
  • Hanaizi Z, van Zwieten-Boot B, Calvo G et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur. J. Cancer 48(2), 237–242 (2012).
  • Ledford H. Melanoma drug wins US approval. Nature 471(7340), 561 (2011).
  • Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin. Oncol. 37(5), 485–498 (2010).
  • Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691–2697 (2012).
  • Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother. Radiopharm. 24(3), 321–325 (2009).
  • Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in braf-mutated melanoma. N. Engl. J. Med. 367(2), 107–114 (2012).
  • Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).
  • Hauschild A, Grob JJ, Demidov LV et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. J. Clin. Oncol. 30(Suppl.), Abstract LBA8500 (2012).
  • Kudchadkar R, Gallenstein D, Martinez AJ, Yu B, Weber JS. Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma. J. Clin. Oncol. 30(Suppl.), Abstract 8582 (2012).
  • Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).
  • Topalian SL, Brahmer JR, Hodi FS et al. PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: clinical activity, safety, and a potential biomarker for response. J. Clin. Oncol. 30(Suppl.), Abstract CRA2509 (2012).
  • Patnaik A, Kang SP, Tolcher AW et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J. Clin. Oncol. 30(Suppl.), Abstract 2512 (2012).
  • Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J. Transl. Med. 10, 107 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.